Clinical Trial Update: A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44 [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study is evaluating the safety and efficacy of ENTR-601-44 in Duchenne muscular dystrophy. The trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• ENTR-601-44

Snippet

Sponsor: Entrada Therapeutics, Inc. | Conditions: Duchenne Muscular Dystrophy (DMD) | Phase 1, Phase 2 | Status: RECRUITING